SMS Pharmaceuticals Ltd (NSE: SMSPHARMA, BSE: 532815) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹4,903 Cr, it ranks #842 by market cap among the 6,197 Indian listed companies on FinBizNet, and #17 of 63 in Pharmaceuticals. At ₹508.50 (as of 16 Nov 2026), the share price is 5.0% below its 52-week high of ₹535.00 and 88.3% above its 52-week low of ₹270.10. The share price is up 75.6% over one year and up 39.1% over three months.
| Current Price | ₹508.50 |
|---|---|
| Market Cap | ₹4,903 Cr |
| NSE Symbol | SMSPHARMA |
| BSE Code | 532815 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 47.1 |
| Return on Equity | 14.31% |
| Return on Assets | 6.65% |
| 52-Week Range | ₹270.10 – ₹535.00 |
| 1-Year Price Change | +75.6% |
| 3-Month Price Change | +39.1% |
| Beta (1Y) | 0.51 |
| Dividend Yield | 0.08% |
| Headquarters | Hyderabad, Telangana |
| Website | www.smslife.in |
| Revenue | ₹316 Cr |
|---|---|
| Net Profit | ₹40 Cr |
| Net Margin | 12.6% |
| EPS (Basic) | ₹4.26 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
SMS Pharmaceuticals Ltd reported revenue of ₹316 Cr in Q2 FY27, up 30.4% from ₹242 Cr in Q2 FY26 and up 52.7% from ₹207 Cr in Q1 FY27. It posted a net profit of ₹40 Cr for the quarter, against a net profit of ₹25 Cr in Q2 FY26 (up 57.4%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹196 Cr (Q1 FY26) to ₹316 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹316 Cr | ₹40 Cr | 12.6% |
| Q1 FY27 | ₹207 Cr | ₹21 Cr | 10.1% |
| Q4 FY26 | ₹238 Cr | ₹33 Cr | 13.7% |
| Q3 FY26 | ₹210 Cr | ₹23 Cr | 11.2% |
| Q2 FY26 | ₹242 Cr | ₹25 Cr | 10.4% |
| Q1 FY26 | ₹196 Cr | ₹20 Cr | 10.5% |
| Q4 FY25 | ₹248 Cr | ₹20 Cr | 8.2% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 68.07% of SMS Pharmaceuticals Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 39.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
1. Pharmaceutical-This segment researches, develops, manufactures, buys, imports, sells, and exports active pharmaceutical ingredients and its intermediates.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| SMS Pharmaceuticals Ltd | ₹4,903 Cr | 47.1 | 14.31% | ₹316 Cr | +75.6% |
Listed by market capitalisation. Ratios are shown for context only.
SMS Pharmaceuticals Ltd is trading at ₹508.50, with a market capitalisation of ₹4,903 Cr.
SMS Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
SMS Pharmaceuticals Ltd has a P/E of 47.1 and a return on equity of 14.31%.
SMS Pharmaceuticals Ltd is listed on the NSE under the symbol SMSPHARMA and on the BSE under the scrip code 532815.
SMS Pharmaceuticals Ltd's share price is up 75.6% over one year and up 39.1% over three months. Its 52-week range is ₹270.10 to ₹535.00.
In Q2 FY27, SMS Pharmaceuticals Ltd reported revenue of ₹316 Cr and net profit of ₹40 Cr, with basic EPS of ₹4.26 (consolidated, parsed from the company's exchange filing).
SMS Pharmaceuticals Ltd reported revenue of ₹316 Cr in Q2 FY27, up 30.4% from ₹242 Cr in Q2 FY26 and up 52.7% from ₹207 Cr in Q1 FY27.
Promoters held 68.07% of SMS Pharmaceuticals Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.